AURKA and prostate carcinoma: Treating these cells with AURKA-GapmeR or Aur-I resulted in decreased AURKA mRNA expression and reduced cell viability in both prostate cancer (Supplementary Figures 8A–C) and pancreatic cancer cells (Supplementary Figures 8D–F).